[go: up one dir, main page]

IN2014DN10084A - - Google Patents

Info

Publication number
IN2014DN10084A
IN2014DN10084A IN10084DEN2014A IN2014DN10084A IN 2014DN10084 A IN2014DN10084 A IN 2014DN10084A IN 10084DEN2014 A IN10084DEN2014 A IN 10084DEN2014A IN 2014DN10084 A IN2014DN10084 A IN 2014DN10084A
Authority
IN
India
Prior art keywords
androgen receptor
receptor modulator
trifluoromethylpyridin
diazaspiro
methylbenzamide
Prior art date
Application number
Inventor
Nicholas D Smith
Mark R Herbert
Ouathek Ouerfelli
Anna Dilhas
Original Assignee
Aragon Pharmaceuticals Inc
Sloan Kettering Inst Cancer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49712550&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014DN10084(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aragon Pharmaceuticals Inc, Sloan Kettering Inst Cancer filed Critical Aragon Pharmaceuticals Inc
Publication of IN2014DN10084A publication Critical patent/IN2014DN10084A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Described herein are amorphous and crystalline forms of the androgen receptor modulator 4 -[7- (6- cyano- 5- trifluoromethylpyridin 3- yl)- 8 oxo -6- thioxo- 5, 7 diazaspiro[3.4]oct- 5- yl]- 2- fluoro- N- methylbenzamide. Also described are pharmaceutical compositions suitable for administration to a mammal that include the androgen receptor modulator, and methods of using the androgen receptor modulator, alone and in combination with other compounds, for treating diseases or conditions that are associated with androgen receptor activity.
IN10084DEN2014 2012-06-07 2013-06-04 IN2014DN10084A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261656888P 2012-06-07 2012-06-07
PCT/US2013/044116 WO2013184681A1 (en) 2012-06-07 2013-06-04 Crystalline forms of an androgen receptor modulator

Publications (1)

Publication Number Publication Date
IN2014DN10084A true IN2014DN10084A (en) 2015-08-21

Family

ID=49712550

Family Applications (1)

Application Number Title Priority Date Filing Date
IN10084DEN2014 IN2014DN10084A (en) 2012-06-07 2013-06-04

Country Status (45)

Country Link
US (9) US9481663B2 (en)
EP (4) EP2858985B1 (en)
JP (3) JP6182209B2 (en)
KR (2) KR102195916B1 (en)
CN (3) CN105693692A (en)
AU (3) AU2013271751B2 (en)
BR (1) BR112014030678A2 (en)
CA (4) CA3055660A1 (en)
CL (1) CL2014003331A1 (en)
CO (1) CO7240407A2 (en)
CR (2) CR20190331A (en)
CY (4) CY1120393T1 (en)
DK (3) DK3533792T3 (en)
EA (3) EA201992010A1 (en)
EC (1) ECSP14030098A (en)
ES (3) ES2670683T3 (en)
FR (1) FR21C1050I2 (en)
GT (1) GT201400283A (en)
HK (2) HK1210175A1 (en)
HR (3) HRP20180902T1 (en)
HU (4) HUE054595T2 (en)
IL (5) IL320522A (en)
IN (1) IN2014DN10084A (en)
LT (4) LT2858985T (en)
LU (1) LUC00236I2 (en)
ME (2) ME03081B (en)
MX (1) MX356754B (en)
MY (1) MY187500A (en)
NI (1) NI201400142A (en)
NL (1) NL301144I2 (en)
NO (1) NO2021046I1 (en)
NZ (2) NZ717683A (en)
PE (3) PE20200725A1 (en)
PH (2) PH12014502714B1 (en)
PL (3) PL3533792T3 (en)
PT (3) PT3348553T (en)
RS (3) RS57370B1 (en)
SG (3) SG10201610248SA (en)
SI (3) SI2858985T1 (en)
SM (3) SMT202100355T1 (en)
TR (1) TR201808939T4 (en)
TW (1) TWI532732B (en)
UA (2) UA115665C2 (en)
WO (1) WO2013184681A1 (en)
ZA (1) ZA201500076B (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008119015A2 (en) 2007-03-27 2008-10-02 Sloan-Kettering Institute For Cancer Research Synthesis of thiohydantoins
SG11201402564QA (en) 2011-12-16 2014-09-26 Olema Pharmaceuticals Inc Novel benzopyran compounds, compositions and uses thereof
PE20200725A1 (en) 2012-06-07 2020-07-21 Aragon Pharmaceuticals Inc CRYSTALLINE FORMS OF THE ANDROGEN RECEPTOR MODULATOR: 4- [7- (6-CYANE-5-TRIFLUOROMETHYLPYRIDIN-3-IL) -8-OXO-6-THIOXO-5,7-DIAZAESPIRO [3,4] OCT-5-IL ] -2-FLUORO-N-METHYLBENZAMIDE) (APALUTAMIDE)
CA2884795C (en) 2012-09-11 2023-10-17 Medivation Prostate Therapeutics, Inc. Formulations of enzalutamide
MX371020B (en) 2012-09-26 2020-01-13 Aragon Pharmaceuticals Inc Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
JOP20200097A1 (en) * 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc Androgen receptor modulator and uses thereof
WO2016029776A1 (en) * 2014-08-26 2016-03-03 Astar Biotech Llc Protein kinase inhibitors
CA2969661C (en) 2014-12-05 2023-04-25 Aragon Pharmaceuticals, Inc. Anticancer compositions
US20170360754A1 (en) 2014-12-05 2017-12-21 Aragon Pharmaceuticals, Inc. Anticancer compositions
KR102387089B1 (en) 2014-12-05 2022-04-14 아라곤 파마슈티컬스, 인코포레이티드 Anticancer compositions
MX2017008050A (en) 2014-12-19 2018-01-18 Lutron Electronics Co MULTICHANNEL LIGHTING ACCESSORY THAT HAS LIGHT ISSUING DIODE CONTROLLERS.
JP2019517497A (en) 2016-06-03 2019-06-24 アラゴン ファーマシューティカルズ，インコーポレイテッド Anticancer composition
EP3555061B1 (en) 2016-12-13 2023-06-07 Watson Laboratories Inc. Solid state forms of apalutamide
SG11202003402QA (en) 2017-10-16 2020-05-28 Aragon Pharmaceuticals Inc Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
WO2019135254A1 (en) * 2018-01-02 2019-07-11 Mylan Laboratories Limited Apalutamide polymorphs and their preparation thereof
CN111344283B (en) * 2018-06-20 2022-08-12 苏州科睿思制药有限公司 Crystal form of ARN-509 and its preparation method and use
WO2020049598A2 (en) 2018-09-08 2020-03-12 Cipla Limited Apalutamide polymorphs
IT201900003839A1 (en) 2019-03-15 2020-09-15 Olon Spa STABLE AMORPHOUS APALUTAMIDE SYNTHESIS
WO2020234817A1 (en) * 2019-05-21 2020-11-26 Laurus Labs Limited Polymorphic forms of apalutamide and its preparation thereof
IT201900010593A1 (en) * 2019-07-01 2021-01-01 Dipharma Francis Srl CRYSTALLINE FORM OF AN ANDROGEN RECEPTOR INHIBITOR
US20220281836A1 (en) * 2019-08-22 2022-09-08 Dr. Reddy's Laboratories Limited Process for the preparation of apalutamide
IT201900015974A1 (en) 2019-09-10 2021-03-10 Olon Spa STABLE CRYSTALLINE APALUTAMIDE IN PURE FORM AND PROCESS FOR ITS PREPARATION
CN110590740A (en) * 2019-09-20 2019-12-20 武汉大学 A kind of apalutamide compound and its pharmaceutical preparation
EP4541786A3 (en) 2020-09-04 2025-08-06 Synthon B.V. Improved process for preparation of apalutamide
CN112679468A (en) * 2021-01-05 2021-04-20 四川科伦药物研究院有限公司 Crystal form of apatamide, preparation method and application
WO2023143090A1 (en) * 2022-01-25 2023-08-03 成都苑东生物制药股份有限公司 Novel crystalline form of apalutamide solvate and preparation method therefor
CN115536634B (en) * 2022-10-17 2024-06-11 上海博悦生物科技有限公司 A kind of synthetic method of apalutamide
CN116332907A (en) * 2023-03-16 2023-06-27 奥锐特药业股份有限公司 A kind of preparation method of amorphous apalutamide
WO2025153768A1 (en) * 2024-01-18 2025-07-24 Nanoform Finland Oyj Composition comprising crystalline nanosized apalutamide

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US7709517B2 (en) * 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
CN101032483B (en) * 2006-03-09 2011-05-04 陈德桂 Hydantoin derivative for adjusting estrogen receptor activity and application thereof
DK2004181T6 (en) 2006-03-27 2023-08-21 Univ California ANDROGEN RECEPTOR MODULATOR FOR THE TREATMENT OF PROSTATE CANCER AND ANDROGEN RECEPTOR-ASSOCIATED DISEASES
JP5350217B2 (en) * 2006-03-29 2013-11-27 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Diarylthiohydantoin compounds
WO2008119015A2 (en) 2007-03-27 2008-10-02 Sloan-Kettering Institute For Cancer Research Synthesis of thiohydantoins
EA028869B1 (en) * 2010-02-16 2018-01-31 Арагон Фармасьютикалс, Инк. Androgen receptor modulators and use thereof
PE20200725A1 (en) 2012-06-07 2020-07-21 Aragon Pharmaceuticals Inc CRYSTALLINE FORMS OF THE ANDROGEN RECEPTOR MODULATOR: 4- [7- (6-CYANE-5-TRIFLUOROMETHYLPYRIDIN-3-IL) -8-OXO-6-THIOXO-5,7-DIAZAESPIRO [3,4] OCT-5-IL ] -2-FLUORO-N-METHYLBENZAMIDE) (APALUTAMIDE)
CN111344283B (en) 2018-06-20 2022-08-12 苏州科睿思制药有限公司 Crystal form of ARN-509 and its preparation method and use

Also Published As

Publication number Publication date
GT201400283A (en) 2017-07-03
US10556882B2 (en) 2020-02-11
LT3533792T (en) 2021-07-26
PE20150631A1 (en) 2015-05-11
US9481663B2 (en) 2016-11-01
CY2021032I1 (en) 2022-03-24
PH12016501470B1 (en) 2021-12-10
IL236055A0 (en) 2015-02-01
LTPA2021525I1 (en) 2021-11-25
PL3533792T3 (en) 2021-11-29
US20180258067A1 (en) 2018-09-13
CA3008345A1 (en) 2013-12-12
EP3533792B1 (en) 2021-05-05
CA3055660A1 (en) 2013-12-12
EP2858985A4 (en) 2016-05-25
HRP20201387T1 (en) 2020-11-27
NZ717683A (en) 2018-04-27
LUC00236I2 (en) 2025-02-03
EP3922629A1 (en) 2021-12-15
ZA201500076B (en) 2016-10-26
JP2015518890A (en) 2015-07-06
MX356754B (en) 2018-06-11
SMT201800311T1 (en) 2018-07-17
NZ702203A (en) 2016-09-30
EP3533792A1 (en) 2019-09-04
ES2809738T3 (en) 2021-03-05
EA201492272A1 (en) 2015-05-29
US10526310B2 (en) 2020-01-07
EP2858985B1 (en) 2018-04-18
IL275413A (en) 2020-07-30
CA3114726A1 (en) 2013-12-12
ME03081B (en) 2019-01-20
BR112014030678A2 (en) 2017-06-27
RS57370B1 (en) 2018-08-31
HK1210175A1 (en) 2016-04-15
FR21C1050I2 (en) 2024-05-24
CA3008345C (en) 2019-10-22
LTC3533792I2 (en) 2024-07-10
HUE050357T2 (en) 2020-11-30
CR20140549A (en) 2015-04-06
EA028791B1 (en) 2017-12-29
JP2017178923A (en) 2017-10-05
US20190241539A1 (en) 2019-08-08
MX2014015005A (en) 2015-09-04
US20200354335A1 (en) 2020-11-12
PT3533792T (en) 2021-06-07
CR20190331A (en) 2019-11-12
PT2858985T (en) 2018-07-10
JP6345821B2 (en) 2018-06-20
IL259738A (en) 2018-07-31
CY1120393T1 (en) 2019-07-10
PE20200795A1 (en) 2020-08-10
UA115665C2 (en) 2017-12-11
IL259738B (en) 2021-06-30
CY2021032I2 (en) 2022-03-24
PL2858985T3 (en) 2018-09-28
US10766875B2 (en) 2020-09-08
SG10201610248SA (en) 2017-02-27
US9994545B2 (en) 2018-06-12
SI3533792T1 (en) 2021-11-30
UA123142C2 (en) 2021-02-24
PE20200725A1 (en) 2020-07-21
CA2875767A1 (en) 2013-12-12
PT3348553T (en) 2020-09-28
PH12014502714A1 (en) 2015-02-02
RS60617B1 (en) 2020-09-30
SI2858985T1 (en) 2018-12-31
IL320522A (en) 2025-06-01
EA201992010A1 (en) 2020-01-24
DK3348553T3 (en) 2020-07-27
US20200115361A1 (en) 2020-04-16
TR201808939T4 (en) 2018-07-23
CY1124831T1 (en) 2022-03-24
WO2013184681A1 (en) 2013-12-12
HRP20210909T1 (en) 2021-09-03
MY187500A (en) 2021-09-24
IL267608B2 (en) 2025-10-01
LT2858985T (en) 2018-09-25
KR20150021993A (en) 2015-03-03
NL301144I2 (en) 2025-03-20
CY1123427T1 (en) 2021-12-31
IL267608B1 (en) 2025-06-01
US20170001977A1 (en) 2017-01-05
DK2858985T3 (en) 2018-05-28
ES2875932T3 (en) 2021-11-11
AU2017200298A1 (en) 2017-02-02
PL3348553T3 (en) 2021-02-08
HK1226066A1 (en) 2017-09-22
HRP20180902T1 (en) 2018-08-24
HUE038082T2 (en) 2018-09-28
CN105693692A (en) 2016-06-22
CA2875767C (en) 2018-08-14
SI3348553T1 (en) 2020-11-30
TW201402561A (en) 2014-01-16
NI201400142A (en) 2016-12-02
US10934271B2 (en) 2021-03-02
US20210163441A1 (en) 2021-06-03
DK3533792T3 (en) 2021-06-28
CN104619692A (en) 2015-05-13
LT3348553T (en) 2020-09-25
NO2021046I1 (en) 2021-11-02
CL2014003331A1 (en) 2016-03-04
EA033956B1 (en) 2019-12-13
US10308630B2 (en) 2019-06-04
KR102195916B1 (en) 2020-12-30
KR20190132543A (en) 2019-11-27
AU2013271751A1 (en) 2014-12-18
AU2017279807A1 (en) 2018-01-25
EP3348553A1 (en) 2018-07-18
SG11201408140QA (en) 2015-01-29
ME03815B (en) 2021-04-20
ES2670683T3 (en) 2018-05-31
EP3348553B1 (en) 2020-07-08
PH12014502714B1 (en) 2015-02-02
FR21C1050I1 (en) 2021-12-10
US20250092011A1 (en) 2025-03-20
HUS2100047I1 (en) 2021-11-29
EP2858985A1 (en) 2015-04-15
KR102062024B1 (en) 2020-01-03
SMT202000496T1 (en) 2020-11-10
AU2017279807B2 (en) 2018-11-08
TWI532732B (en) 2016-05-11
JP2018141009A (en) 2018-09-13
US12018008B2 (en) 2024-06-25
SMT202100355T1 (en) 2021-07-12
PH12016501470A1 (en) 2017-07-10
RS61988B1 (en) 2021-07-30
AU2013271751B2 (en) 2017-02-23
JP6182209B2 (en) 2017-08-16
US20190330182A1 (en) 2019-10-31
ECSP14030098A (en) 2016-01-29
SG10201610249TA (en) 2017-02-27
CN113135892A (en) 2021-07-20
AU2017200298B2 (en) 2017-09-28
IL267608A (en) 2019-08-29
US20150133481A1 (en) 2015-05-14
HUE054595T2 (en) 2021-09-28
EA201791592A1 (en) 2018-01-31
CO7240407A2 (en) 2015-04-17

Similar Documents

Publication Publication Date Title
IN2014DN10084A (en)
TN2012000126A1 (en) Polycyclic compounds as lysophosphatidic acid receptor antagonists
MX2013006040A (en) Lysophosphatidic acid receptor antagonists and their use in the treatment fibrosis.
MY163055A (en) Polycyclic antagonists of lysophosphatidic acid receptors
NZ702663A (en) Nuclear transport modulators and uses thereof
IN2012DN02177A (en)
IN2012DN00754A (en)
UA102857C2 (en) Quinuclidine carbonate derivatives and use thereof
WO2014070991A3 (en) Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists
UA107334C2 (en) Alkaloid aminoester derivatives and their drug compositions
MX2015007051A (en) Diazole lactams.
MX353331B (en) Solid forms of (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihy dro-3'h-spiro-[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine hydrochloride.
WO2015079415A9 (en) Amorphous cobicistat solid dispersion
UA115310C2 (en) SPIROTSYKLICHNI compounds based on derivatives of 2-OKSINDOLU, CONTAINING CORE SPIRO [indole-3,1'-pyrrolo [3,4-c] pyrrole] and the remains of biogenic sulfur-containing amino acids, the way they receive and pharmaceutical compositions on their basis
TN2011000063A1 (en) Quinuclidine carbonate derivatives and medicinal composition thereof